BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Fluidigm Corporation Releases Access Array(TM) System Amplicon Tagging Protocol For Sequencing With 454 Life Sciences Gs Flx Titanium Series Reagents


4/27/2010 3:42:44 PM

SOUTH SAN FRANCISCO, Calif., Apr. 26, 2010 – Fluidigm Corporation today announced the release of a protocol for the Access Array™ System that enables sequencing of amplicon libraries using GS FLX Titanium Series reagents on the 454 GS FLX sequencing system. The Access Array integrated fluidic circuit (IFC) automatically generates emPCR-ready libraries by simultaneously combining 48 samples and 48 primer sets to produce 48 uniquely-barcoded samples per chip for approximately $7 (U.S.) per sample.

Fluidigm’s Access Array IFC, when used with a 454 Titanium sequencer, can capture up to 24 kb of sequence data per sample, or 1.15 MB per IFC.

“The Access Array System has already been adopted by users around the world for projects focused on research of cancer, miRNA, and population genetics that require inexpensive sequencing of targeted enrichment regions for hundreds or thousands of samples,” noted Mike Lee, Fluidigm’s Senior Director of Marketing. “The addition of the GS FLX Titanium Series reagents with longer reads continues to expand the amount of sequence that can be captured using our Access Array System. The protocol will benefit our mutual customers by producing more sequence data in the researcher’s regions of interest,” he added.

Sequencing library preparation for next-generation sequencers is by far the most time and labor demanding component of the entire next-generation sequencing process. While necessary for whole genome sequencing studies, the process can be almost entirely eliminated for targeted re-sequencing projects when using Fluidigm’s Access Array System. By incorporating adaptor sequences into the primer design, the final PCR product is ready for emulsion PCR as it already contains the necessary capture sequences.

The 48.48 Access Array IFC is the first chip that features the ability to recover reaction products automatically. Once sample processing has been completed, the IFC automatically returns the samples to inlets from which it can be easily extracted and readied for sequencing.

About Fluidigm

Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit (IFC) systems that significantly improve productivity in life science research. Fluidigm’s IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These “integrated circuits for biology” are made possible by miniaturizing and integrating liquid handling components on a single microfluidic device (IFC). Fluidigm’s systems, consisting of instrumentation, software and single-use chips, increase throughput, decrease costs and enhance sensitivity compared to conventional laboratory systems. Fluidigm products have not been cleared or approved by the Food and Drug Administration for use as a diagnostic and are only available for research use.

For more information, please visit www.fluidigm.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES